Clinical Trial Update: Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant study evaluating nab-paclitaxel, oxaliplatin, S-1, and sintilimab in early-onset resectable gastric cancer; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Stomach Adenocarcinoma

Drugs mentioned

• Nab-paclitaxel (Abraxane) (nab-paclitaxel)
• Oxaliplatin (Eloxatin) (oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (Tyvyt) (sintilimab)

Snippet

Sponsor: zhoujing | Conditions: Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING